Delivery Order SPE2DE21D0007-SPE2D625F0SBW
- Not listed
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order valued at $1,109.97 to Ortho-Clinical Diagnostics, Inc. for Anti-A Bioclone 15x10ML on August 1, 2025, with an ultimate completion date of August 6, 2025. The contract utilizes fixed-price pricing with economic price adjustment and carries no set-aside designation, indicating open competition. Performance will occur at the contractor's facility in Raritan, New Jersey. Ortho-Clinical Diagnostics, Inc., a for-profit...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order valued at $1,037.23 to Ortho-Clinical Diagnostics, Inc. for Reagent Anti-D Bioclone 150ML Monoclonal on September 3, 2025. The contract employs firm fixed-price pricing with no set-aside designation, indicating open competition. The award will be performed at the contractor's facility in Raritan, New Jersey, with an ultimate completion date of September 8, 2025. Ortho-Clinical Diagnostics, Inc., a for-profit medical...
- Ortho-Clinical Diagnostics, Inc., headquartered in Raritan, New Jersey, was awarded a delivery order valued at $1,910.02 on August 6, 2025, for Anti-A Bioclone 15x10ml medical diagnostic reagents. The contract, which will be completed by August 27, 2025, was issued without a set-aside designation, indicating open competition. The funding originates from the Medical Supply Chain within the Department of Defense, with the place of performance located in Raritan, New Jersey. This delivery order...
- Ortho-Clinical Diagnostics, Inc. was awarded a delivery order contract on July 11, 2025, by the Medical Supply Chain division of the Department of Defense for the supply of Anti-A Bioclone 15x10ml reagents, valued at $1,156.61. The contract employs fixed-price pricing with economic price adjustment provisions and is scheduled for ultimate completion by August 1, 2025. The work will be performed at the company's facility in Raritan, New Jersey. No set-aside designation was used in this...
- The U.S. government's Defense Logistics Agency Troop Support Medical awarded a $1,832.54 fixed price delivery order contract to Ortho-Clinical Diagnostics, Inc. for the purchase of 4564336504 ANTI-A BIOCLONE 15X10ML medical supplies. The contract has an ultimate completion date of May 10, 2024. Ortho-Clinical Diagnostics, Inc. is a for-profit medical equipment manufacturer that provides a range of diagnostic solutions to federal agencies, including the Department of Veterans Affairs and...
- Ortho-Clinical Diagnostics, Inc. was awarded a delivery order valued at $1,871.28 for Anti-A Bioclone 15x10ml on July 21, 2025, with an ultimate completion date of July 24, 2025. The contract utilizes fixed-price pricing with economic price adjustment and was awarded without a set-aside designation, indicating open competition. The work will be performed in Raritan, New Jersey, and is funded by the Defense Health Agency's Medical Supply Chain, which supports critical medical diagnostic...
- This is a $1,832.54 delivery order awarded by the Medical Supply Chain, a division of the Defense agency, to Ortho-Clinical Diagnostics, Inc., a for-profit medical equipment manufacturer. The contract is for the supply of "ANTI-A BIOCLONE 15X10ML", a medical diagnostic product, with a period of performance through May 2025. The contract has a fixed price with economic price adjustment pricing type and does not utilize any set-aside designations. Ortho-Clinical Diagnostics, Inc. is a...
- Ortho-Clinical Diagnostics, Inc. has been awarded a delivery order contract by the Defense Medical Supply Chain with a ceiling value of $1,767.32 for Rght Anti-A B Bcln 10ml Btl Orth Bb—a specialized blood bank diagnostic reagent. The contract award is dated July 18, 2025, with an ultimate completion date of July 30, 2025, and will be performed at the company's facility in Raritan, New Jersey. This delivery order employs fixed-price contracting with economic price adjustment and was awarded...
- Ortho-Clinical Diagnostics, Inc. was awarded a delivery order on August 6, 2025, by the Defense Medical Supply Chain to supply ANTI-A BioclOne 15x10mL, a diagnostic reagent product. The contract is valued at $1,109.97 under a fixed-price arrangement with economic price adjustment provisions, with an ultimate completion date of August 11, 2025. The work will be performed at the company's facility in Raritan, New Jersey. No set-aside designation was utilized for this award, indicating open...
- This is a $1,832.54 fixed-price delivery order awarded to Ortho-Clinical Diagnostics, Inc., a for-profit medical equipment manufacturer, by the Medical Supply Chain division of the Defense agency. The contract is for the supply of ANTI-B BIOCLONE 15X10ML medical products, with a completion date of June 6, 2025. Ortho-Clinical Diagnostics, Inc. is a self-certified HUBZone joint venture registered in SAM.gov and specializes in providing advanced diagnostic solutions to federal healthcare agencies,...
- SPE2DE21D0007Indefinite Delivery Contract
- SPE2DE21D0007-SPE2D625F0SBWDelivery Order
The U.S. Defense Department's Medical Supply Chain agency awarded a delivery order valued at $1,109.97 to Ortho-Clinical Diagnostics, Inc. for Anti-B Bioclone 15x10ML on August 11, 2025, with completion targeted for August 14, 2025. The contract utilizes fixed-price pricing with economic price adjustment and carries no set-aside designation, indicating open competition. Ortho-Clinical Diagnostics, headquartered in Raritan, New Jersey, is a for-profit medical equipment manufacturer specializing in advanced diagnostic solutions for federal healthcare agencies. The company holds HUBZone joint venture status and maintains a strong track record of federal contract performance through various Defense Health Agency, Department of Veterans Affairs, Indian Health Service, and National Institutes of Health engagements. This delivery order represents part of Ortho-Clinical Diagnostics' broader federal engagement, which includes multiple significant indefinite delivery vehicles such as a $1.6 million indefinite delivery contract with Veterans Integrated Service Network 12 for Ortho Vision Analyzer reagents and services. The company's federal portfolio emphasizes providing critical laboratory testing infrastructure, including blood bank analyzers, clinical chemistry systems, and associated consumables—all essential to federal healthcare operations. The Anti-B Bioclone reagent being supplied under this order supports immunodiagnostic testing capabilities within the Defense Department's medical supply chain network.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 8/11/25 |